Itepekimab is being jointly developed by Sanofi and Regeneron under a global collaboration agreement and is currently in clinical development programs for CRSwNP (phase 3), non-cystic fibrosis ...

About Itepekimab Itepekimab, which was invented using Regeneron’s proprietary VelocImmune® technology, is a fully human monoclonal antibody that binds to and inhibits interleukin-33 (IL-33), an ...

Itepekimab, an investigational monoclonal antibody for chronic obstructive pulmonary disease (COPD), demonstrated mixed results in a pair of phase 3 studies evaluating the treatment in former ...

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is one of the Best Extremely Profitable Stocks to Buy Right Now . On July 22, ...

Treatment with itepekimab resulted in a lower incidence of events indicating loss of asthma control and improved lung function in adults with moderate to severe asthma, according to new phase 2 ...

AERIFY-1 study met its primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former smokers regardless of eosinophilic phenotype and provided a ...

The safety profile of itepekimab observed in the Phase 3 trials was consistent with prior clinical trials. Anti-drug antibodies were rare and had no apparent impact on itepekimab drug levels.

Itepekimab met the primary endpoint in one of two COPD phase 3 studies AERIFY-1 study met its primary endpoint of a statistically significant reduction in moderate or severe exacerbations in ...

Itepekimab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement and is currently in clinical development programs for chronic rhinosinusitis with nasal polyps ...

About Itepekimab Itepekimab, which was invented using Regeneron’s proprietary VelocImmune® technology, is a fully human monoclonal antibody that binds to and inhibits interleukin-33 (IL-33), an ...

Itepekimab was generally well tolerated in both AERIFY-1 and AERIFY-2, with safety consistent with prior clinical trials Regeneron and Sanofi are assessing the data and will discuss next steps ...